Objectives. The multisystem manifestations of SSc can greatly impact patients' quality of life. The aim of this study was to identify factors associated with disability in SSc.
Introduction
SSc is a rare, clinically heterogeneous multisystem disorder which greatly affects the patients' physical and psychological functioning and impairs their ability to participate in work and social activities. Substantial morbidity results from digital ulcers (DUs), skeletal muscle weakness, contractures, cardiopulmonary and gastrointestinal involvement [13] . One of the most formidable goals of care is to alleviate symptoms and disability and to improve the health-related quality of life (QoL) and functional ability [4] .
Whereas physicians tend to emphasize objective measures of disease status, patients may perceive other aspects of their disease as more disabling or burdensome [5] . The evaluation of SSc severity and its impact on activities of daily living requires several measures due to multiple organ involvement; single organ outcome measures only provide limited information [6] .
The HAQ is one of the most commonly used measures of disability in musculoskeletal disorders and is also used in SSc as a simple, inexpensive and practical way to reflect the patients' perspective [710] . It is a self-reported questionnaire consisting of 20 questions split across eight domains, addressing rising, eating, walking, hygiene, dressing, reach, grip and usual activities [11] . The HAQ was extended to form the scleroderma HAQ (SHAQ), a more disease-specific disability scale that incorporates the HAQ and five scleroderma-related visual analogue scales (VASs) into one score [6] . The five VASs in the SHAQ assess the level of impairment due the complications frequently observed in SSc outside the musculoskeletal system, namely RP, DUs, gastrointestinal symptoms, respiratory symptoms, as well as the overall severity of the disease from the patients' perspective [6] . The SHAQ is a reliable and valid measure of functional disability in SSc [68, 12, 13] .
Several studies have assessed the impact of selected SSc-specific symptoms on patients' life [3, 1417] , or assessed overall QoL or functional disability and factors associated with it [1, 13, 18] . However, due to the rarity of the disease, most of these studies have a limited sample size and focus on sub-populations, for example only patients with DUs or patients with pulmonary hypertension [1821] . Recently, one large internet-based survey assessed patients' perception of factors impacting on their daily lives, as well as health-related QoL [22] . This study, however, was a purely patient-based survey with no linkage to clinical data.
Our aim was therefore to prospectively analyse functional disability in a large cohort of SSc patients not selected for a particular organ manifestation, and to identify clinical factors contributing to impairment.
Methods

Study population and design
The DeSScipher (to decipher the optimal management of SSc [23, 24] ) project is a multinational, longitudinal study embedded in the European Scleroderma Trials and Research (EUSTAR) group database [25, 26] . The DeSScipher project consisted of five observational trials (OTs) focusing on DU, hand arthritis, interstitial lung disease, pulmonary hypertension and severe heart disease. However, DeSScipher patients as such were not selected for any specific organ manifestations as the DeSScipher cohort consisted of EUSTAR patients being followed at DeSScipher centres during the DeSScipher project regardless of organ manifestations and eligibility into any of the DeSScipher OTs (see the DeSScipher website for more detail [24] ).
DeSScipher data were collected prospectively in a multicentre approach. Data collection for the DeSScipher project started in March 2013; however, the recording of the SHAQ within the DeSScipher database only started in October 2014, and was independent of particular organ manifestations, SSc treatments or eligibility for a specific DeSScipher OT. Data for this study were exported in August 2016. Each DeSScipher centre obtained ethical approval from its local ethics committee; written informed consent according to the Declaration of Helsinki was required from each patient prior to enrolment.
All patients had to fulfill either the 1980 ACR criteria for SSc or the 2013 ACR/EULAR criteria and were eligible for this analysis if they were above 18 years of age and had at least one SHAQ available [6, 27, 28] . Patients were classified as dc or lcSSc depending on the most severe skin involvement at the time of the study visit or any prior visit.
The HAQ built into the SHAQ has a recall period of 7 days, ranges from 0 to 3 and can be categorized into mild to moderate difficulty (score of 0 to <1), moderate to severe disability (score of 1 to <2) and severe to very severe disability (score of 23) [10, 11] . The VAS scales in the SHAQ assess the interference of the disease with daily activities and range from 0 (not limiting activities) to 100 (very severe limitation). In the original version of the SHAQ no combined score was built; instead the HAQ and the five VASs were assessed separately [6] . Georges et al. [29] proposed to average the eight HAQ categories and the five VASs (each downscaled to range from 0 to 3) into a composite SHAQ score ranging from 0 to 3. For this cross-sectional study, the first SHAQ recorded was analysed.
Statistical analysis
Depending on the categorical or continuous nature of the variables, frequencies and percentages or means (S.D.) were calculated. For categorical variables, between group comparisons were carried out using chi-squared tests or Fisher's exact tests; t-tests were used for continuous variables. Missing data of covariates were imputed using multiple imputations by chained equations [30, 31] .
After defining possible predictors of functional disability a priori (Table 1) , predictors were identified using univariable and multivariable linear regression analyses. We decided not to include the SSc subset of the patients and sclerodactyly in the multivariable model, as these variables are strongly related to the modified Rodnan skin score.
To compare levels of disability in patients with diffuse SSc and limited SSc we reduced the original model to factors that were strong and clinically significant predictors of functional disability in the overall patient group or were defined a priori.
The minimal clinical important difference (MCID) of the HAQ is stated to be 50.22 [32] . As the SHAQ is based on the HAQ and has the same range, we applied this threshold also to the SHAQ. We treated a difference of 510 mm as the MCID for the VAS components [3234] . All analyses were performed with Stata/IC 13.1 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
At the time of the data export, 944 (38%) of the 2488 adult DeSScipher patients had a SHAQ score. During the time of the SHAQ collection, 2084 patients had a visit after the introduction of the SHAQ, and therefore 45% of eligible patients had a SHAQ score available; the demographic and disease characteristics of this study population are listed in Table 2 . Of the 944 patients, 115 (12.2%) fulfilled only the 2013 ACR/EULAR criteria but not the 1980 ACR classification criteria for SSc. Patients included in the study were of similar age and sex distribution as the patients excluded for the lack of a SHAQ. Additionally, both groups had comparable disease durations and SSc subset distributions (data not shown).
Functional disability
The mean (S.D.) SHAQ score was 0.87 (0.66); 59.5% of the patients were in the lowest SHAQ category (score of 0 to <1), 34.0% had a score of 1 to <2 and 6.5% were in the category regarded as severe to very severe disability The mean (S.D.) HAQ score was 0.92 (0.78); 53.8% of patients fell into the mild to moderate difficulty category (score <1), 34.1% into the moderate to severe disability (score 51 to <2) and 12.1% into the severe to very severe disability (score 52) category. Patients with diffuse SSc had a higher mean HAQ score than patients with lcSSc 
Predictors to functional disability
We first assessed the association of variables with the SHAQ with univariable analysis. The strongest predictor of disability was dyspnoea. In patients with modified The multivariable analysis of the SHAQ was in line with the results observed in univariable analysis. Dyspnoea remained the strongest predictor of functional disability. The SHAQ scores reported by patients with modified NYHA class IV, III or II were on average 0.62, 0.53 and 0.21 U higher than that of patients with modified NYHA class I (Fig. 1) . In addition, both the presence of FM and muscle weakness were associated with higher levels of disability. Patients with FM reported on average a SHAQ value 0.37 U higher than that of patients without FM, and patients experiencing muscle weakness recorded on average a 0.27 U higher SHAQ (Fig. 1) . Other factors contributing to disability included the presence of DUs, oesophageal, gastric and/or intestinal symptoms, joint contractures, and a more severe skin involvement (Fig.  1) . Only dyspnoea, FM and muscle weakness remained clinically significant contributors to functional disability when applying the 0.22 threshold for the MCID [32] .
None of the objective clinical measures were associated with a higher SHAQ score (Fig. 1) . The changes in the average SHAQ scores were (in order of absolute magnitude): 10% higher left ventricular ejection fraction (À0.05 U), 10 mmHg higher systolic pulmonary artery pressure as estimated by echocardiography (0.04 U), presence of conduction blocks (À0.04 U), presence of a diastolic dysfunction (À0.03 U), 10% of predicted lower forced vital capacity (À0.02 U), 10% of predicted lower single breath diffusing capacity for carbon monoxide (À0.01 U) and the presence of pericardial effusion (À0.01 U).
Patients experiencing any gastrointestinal involvement (presence of oesophageal, gastric or intestinal symptoms) reported a clinically significant higher SHAQ [0.24 U (95% CI: 0.15, 0.32)] than patients reporting no gastrointestinal involvement. In multivariable analysis, patients with multiple simultaneous gastrointestinal symptoms also had higher SHAQ scores than those featuring symptoms in only one or two regions of the gastrointestinal tract (oesophagus, stomach or intestine). Patients reporting oesophageal, gastric and intestinal symptoms simultaneously had, on average, a SHAQ score of 0.46 U (95% CI: 0.34, 0.58) higher than patients reporting no gastrointestinal symptoms. Similarly, patients with symptoms in two or one gastrointestinal region also reported a higher functional disability than patients with no gastrointestinal problems [0.28 U (95% CI: 0.18, 0.38) and 0.13 U (95% CI: 0.04, 0.22), respectively]. The analysis of the HAQ scores showed impairment similar to the SHAQ. In univariable analysis in patients in modified NYHA functional class IV, the HAQ was on average 1.32 U (95% CI: 0.88, 1.75) higher than in patients in modified NYHA class I; respective values for patients in modified NYHA class III were 0.96 U (95% CI: 0.78, 1.14) and in patients in modified NYHA class II 0.46 U (95% CI: 0.37, 0.56), all vs modified NYHA I. Other factors associated with higher HAQ scores were (in order of magni- In multivariable analyses, patients with modified NYHA functional class IV had an average HAQ score of 0.70 U higher than patients with modified NYHA functional class I (modified NYHA class III: 0.54 U; modified NYHA class II: 0.23 U; all vs modified NYHA class I). The presence of FM (increase of 0.33 U) and of muscle weakness (increase of 0.32 U) were also strong and clinically important predictors of elevated HAQ scores (Fig. 1) . The presence of any gastrointestinal problems, that is, the presence of oesophageal, stomach or intestinal symptoms, led to a clinically important average increase of 0.22 HAQ U (95% CI: 0.11, 0.31). Similarly, the number of simultaneous gastrointestinal symptoms was a strong predictor of an elevated HAQ; for patients reporting each of oesophageal, gastric and intestinal symptoms, the average HAQ increase was 0.44 U (95% CI: 0.30, 0.58), for patients reporting symptoms in two gastrointestinal regions the average increase was 0.26 U (95% CI: 0.14, 0.38) and for patients reporting symptoms in only one gastrointestinal region the HAQ increase was 0.11 U (95% CI: 0.002, 0.22) compared with patients reporting no gastrointestinal symptom.
FIG. 1 Predictors for the composite scleroderma HAQ and the HAQ scores in SSc patients
Multivariable regression coefficients with 95% CI for the composite SHAQ and the HAQ scores (both ranging from 0 to 3). Regression coefficients and their 95% CI are presented in bold if the 95% CIs do not include zero. DLCO: single breath diffusing capacity for monoxide; FVC, forced vital capacity; LVEF: left ventricular ejection fraction; mRSS; modified Rodnan skin score; NYHA: New York Heart Association; PAPsys systolic; pulmonary artery pressure as estimated by echocardiography; Scl-70: anti-topoisomerase autoantibodies; yrs: years.
Disability in the SSc subsets
In patients with diffuse SSc (n = 344), the factors contributing to a clinically meaningful SHAQ increase were similar to those contributing in patients with lcSSc (n = 532; Fig. 2 ), namely dyspnoea (modified NYHA III/IV vs modified NYHA I/II increase of 0.42 U), muscle weakness (increase of 0.36 U) and gastrointestinal symptoms (Fig. 2) . Patients with fibromyalgia also had on average a 0.25 U higher SHAQ (Fig. 2) .
In both SSc subsets, the presence of multiple simultaneous gastrointestinal symptoms also strongly predicted disability. In patients with diffuse SSc, the SHAQ was on average 0.39 U (95% CI: 0.19, 0.59) higher in patients simultaneously reporting oesophageal, gastric and intestinal symptoms than in patients not reporting gastrointestinal symptoms. In the group of patients with lcSSc, this difference was even greater [0.60 U (95% CI: 0.44, 0.78)].
Discussion
Our study is by far the largest linking patients' self-assessed disability with objective clinical data and is also the first of its size to analyse a comprehensive set of clinical factors contributing to disability in an SSc population not selected for a particular organ manifestation or subset. The physicians' main attention while caring for SSc patients is often focused on objective measures of function, for example pulmonary function tests. These measures may, however, not reflect the patient's experience with the disease, self-perceived impact on QoL and functional capacity.
The most important factors predicting functional disability in our study were dyspnoea, gastrointestinal symptoms, FM, muscle weakness and the presence of DU, in line with the results of smaller studies [5, 15, 16, 20, 21, 35, 36] . Thus, there is a major difference between the factors driving patient perceived levels of disability and those emphasized by physicians (i.e. lung function testing, pulmonary arterial pressure estimates, etc.). In clinical practice, though, objective quantifications of gastrointestinal symptoms, FM, muscle weakness and DUs are rarely performed. Comparing the four specific VASs, the highest patient-rated limitation of daily life was due to RP, followed by pulmonary and gastrointestinal symptoms. A similar finding was observed in two surveys in which SSc patients ranked RP, gastrointestinal complications, musculoskeletal involvements and pain among the symptoms influencing their daily life the most [22, 37] . In contrast to our study, Strickland et al. [18] only found an association between functional disability and gastrointestinal involvement, but not with any other demographic or clinical variable. Similarly, Chow et al. [19] did not detect a correlation between NYHA functional class, the strongest predicting factor in our study, and functional disability in SSc patients with pulmonary arterial hypertension. One likely reason for this discrepancy is the limited sample size of 68 and 41 patients, respectively. Additionally, in the study by Chow et al. [19] the selection of patients might be another likely reason as the investigators only included SSc patients with pulmonary arterial hypertension and dyspnoea resulting in a distribution of NYHA classes skewed towards the higher classes.
The overall level of disability as identified by the HAQ in our European SSc population is > 4 times higher than that reported in the general French population, and comparable to that reported in other systemic rheumatic diseases   FIG. 2 Predictors for the composite scleroderma HAQ in patients with diffuse and patients with lcSSc Demographic and disease characteristic as well as multivariable regression coefficients with 95% CI for the composite SHAQ score (range 0 to 3) for patients with diffuse and limited cutaneous SSc. Regression coefficients and their 95% CI are presented in bold if the 95% CIs do not include zero. Age, increase per 10 years; DLCO and FVC, increase per 10% of predicted; dyspnoea, modified NYHA functional class III/IV vs modified NYHA functional class I/II; mRSS, increase per 5 points; all others, yes/no. DLCO: single breath diffusing capacity for monoxide; FVC: forced vital capacity; mRSS: modified Rodnan skin score; NYHA: New York Heart Association. [2, 38, 39] . The HAQ score observed in our cohort is similar to that found in other SSc studies, with about half of patients considering themselves to be mildly to moderately disabled [14, 18] . However, the SHAQ scores as well as the VASs encompassed in it are lower in our study than in a French single-centre study [29] . This discordance might be explained by the lower percentage of dcSSc patients in our population.
In patients with dcSSc the level of disability was significantly higher than in patients with limited SSc. The differences between SSc subsets in our cohort were, however, smaller than those reported previously in much smaller studies [13, 18, 29] . Interestingly, the main factors contributing to disability, namely dyspnoea, gastrointestinal symptoms, muscle weakness, DUs and pain, were similar in the SSc subsets. This goes in line with a recent survey by Frantz et al. [22] that identified no difference of patientperceived impact of organ involvement on QoL between SSc subsets.
There are limitations of our study. We only had SHAQ data of about 45% of all eligible patients. A selection bias might have occurred in both directions, that is, patients with more severe disease may have felt too unwell to fill in the SHAQ questionnaire, or were actually more likely to fill in the questionnaire as they felt more impaired. The demographic characteristics of the patients included in this study were, however, comparable to the DeSScipher patients without an available SHAQ, as were the disease duration and the distribution of the SSc subsets. One problem often arising in observational studies is the data quality. However, one big strength of the DeSScipher cohort is that there were various strategies in place to enhance data quality, including on-site data monitoring. Thus, our results are likely to better reflect the bigger SSc community than those of previous studies, particularly due to the multicentre and multinational nature of this study.
In conclusion, this study demonstrates significantly impaired functional capacity in a large proportion of SSc patients, and demonstrates that dyspnoea, pain, DUs, muscle weakness and gastrointestinal symptoms are the most important contributors perceived by the patients. Our finding that objective measures are not associated with patient-perceived disability is a clarion call to researchers and clinicians that the many and multi-faceted aetiologies of disability in SSc are poorly understood. Further, the root causes impacting disability are likely overlooked and poorly assessed in the clinical setting. As a result of this, QoL is not yet targeted by our treatment armamentarium.
